JSA advised Temasek in its investment in Molbio Diagnostics.
Goa-based Molbio Diagnostics is known for its ‘Truenat’ technology — a portable, battery-operated real-time PCR platform that can be used for testing infectious diseases, including TB, COVID-19, Hepatitis-C virus, human papillomavirus, influenza and vector-borne diseases like dengue, chikungunya and malaria. The Company’s Truenat portable technology platform enables early and accurate diagnosis of infectious diseases and initiation of correct treatment right at the first point of contact and can be deployed at all levels of the healthcare chain, including very remote and inaccessible areas.
Motilal Oswal Alternates is an existing investor in Molbio Diagnostics. JSA had advised Motilal Oswal at the time of its investment as well.
JSA Transaction Team comprised Partners – Vikram Raghani, & Birbahadur Sachar, Principal Associate – Yashvi Singh, and Associate – Rishabh Sheth.
JSA Competition Team comprised Partner & Head of Practice (Competition Law) – Vaibhav Choukse, Principal Associate – Ela Bali, Senior Associate – Aditi Khanna, and Associate – Faiz Siddiqui.
Aditi is a competition / antitrust lawyer, who recently completed her post-graduation.